NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

RegulatoryNEO212Positive

AI Analysis

Summary

NeOnc received FDA written feedback on NEO212's chemistry, manufacturing, and controls (CMC) development, including guidance on transitioning from capsule to tablet formulation.

Outcome Details

FDA provided written feedback on CMC development and capsule-to-tablet transition

Importance:4/10

Sentiment:

0.30

FDA feedbackCMCformulation developmentmanufacturing

Related Companies

$NTHI

Read the original article

Published by yahoo_finance on July 15, 2026 1:25 PM

Read Original